GO
Loading...

Health Care Equipment

More

  • PARIS, June 14- French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes. Under the terms of a memorandum of understanding, Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.

  • *China launches anti-dumping probe into dialysis kit makers. SHANGHAI, June 13- China on Friday launched an anti-dumping investigation into makers of blood dialysis equipment in the European Union and Japan, including market leader Fresenius Medical Care AG& Co KGaA, challenging the international firms who currently dominate the global and Chinese markets.

  • CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.

  • Medtronic mulls bid for Smith & Nephew: Report Wednesday, 4 Jun 2014 | 3:36 PM ET
    Medtronic office in Toronto.

    One of the world's largest makers of medical devices, Medtronic, is considering a takeover of London-based Smith & Nephew, Bloomberg said.

  • June 4- HeartWare International Inc said it received a warning letter from the U.S. Food and Drug Administration following an inspection of its manufacturing plant in Florida in January. HeartWare has also been asked to address issues related to its production and quality procedures and fix problems cited in FDA's inspection.

  • Medical device maker HeartWare gets FDA warning letter Wednesday, 4 Jun 2014 | 7:37 AM ET

    June 4- HeartWare International Inc said it received a warning letter from the U.S. Food and Drug Administration following an inspection of its manufacturing plant in Florida in January. The FDA has not restricted the use of HeartWare devices, the company said in a statement.

  • May 28- Medtronic Inc has agreed to pay the United States $9.9 million to settle claims that the company used kickbacks to induce doctors to implant its pacemakers and defibrillators in patients, the U.S. Department of Justice said.

  • Medtronic settles U.S. kickbacks case over pacemakers Wednesday, 28 May 2014 | 3:44 PM ET

    May 28- Medtronic Inc has agreed to pay $9.9 million to the United States to settle claims it used kickbacks to induce doctors to implant its pacemakers and defibrillators in patients.

  • May 20- Medtronic Inc agreed to pay more than $1 billion to rival Edwards Lifesciences Corp to settle patent litigation and keep its CoreValve artificial heart valve on the U.S. market. Edwards was first to market with its Sapien technology in 2011 in the United States, while Medtronic received U.S. regulatory approval for CoreValve in January.

  • May 20- Medtronic Inc agreed to pay royalties to rival Edwards Lifesciences Corp so it can continue to sell its CoreValve replacement heart valves, the medical device maker said on Tuesday. Medtronic said it would give Edwards a one-time payment of $750 million, plus ongoing royalty payments through April 2022, based on a percentage of CoreValve sales.

  • May 20- Medtronic Inc said on Tuesday it agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement that allows Medtronic to continue to sell its CoreValve replacement heart valves.

  • AstraZeneca Chair: Shareholders, 'vote me away' Monday, 19 May 2014 | 11:14 AM ET

    As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.

  • Boston Scientific subpoenaed over heart device Friday, 9 May 2014 | 6:25 AM ET
    U.S. Department of Health and Human Services building, Washington, DC.

    Boston Scientific received a subpoena this week from the Department of Health and Human Services seeking information about its defibrillators.

  • Boston Scientific gets subpoena over defibrillators Thursday, 8 May 2014 | 11:37 PM ET

    May 8- Medical device maker Boston Scientific Corp said it received a subpoena this week from the Department of Health and Human Services seeking information about the performance of some of its implanted defibrillators. Boston Scientific, which competes with Medtronic Inc and St. Jude Medical Inc in selling ICDs, said it is cooperating with the request.

  • April 29- Boston Scientific Corp's quarterly revenue fell short of expectations due to lower sales of its implantable defibrillators and pacemakers, sending its shares down as much as 6 percent. Boston Scientific said it expected subcutaneous ICD sales of over $75 million in 2014..

  • UPDATE 1-Zimmer to buy Biomet in $13.35 bln deal Thursday, 24 Apr 2014 | 7:48 AM ET

    April 24- Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio of products that treat bone and joint-related disorders.

  • Zimmer to buy Biomet in $13.35 bln deal Thursday, 24 Apr 2014 | 7:18 AM ET

    April 24- Medical device maker Zimmer Holdings Inc said it would acquire orthopedic products company Biomet Inc in a deal valued at about $13.35 billion.

  • April 22- Intuitive Surgical Inc on Tuesday lowered its forecast for procedure growth for its da Vinci surgical robots, citing a slowdown in U.S. gynecology procedures. The medical device maker said it now expects da Vinci procedure growth in a range of 2 percent to 8 percent, down from the prior forecast of 9 percent to 12 percent.

  • April 22- The U.S. Food and Drug Administration on Tuesday proposed speeding up medical device approvals for patients who have no other treatment options through a new program focused on earlier and more frequent interactions between companies and FDA staff.

  • The proposed Expedited Access Premarket Approval Application program would feature earlier and more frequent interactions between companies and FDA staff. The program is not a new pathway to market, the FDA said, but rather a change in approach aimed at reducing the time it takes to develop a product and get it to market.